Integrin αvβ1 facilitates ACE2-mediated entry of SARS-CoV-2

Virus Res. 2024 Jan 2:339:199251. doi: 10.1016/j.virusres.2023.199251. Epub 2023 Nov 2.

Abstract

Integrins have been suggested to be involved in SARS-CoV-2 infection, but the underlying mechanisms remain largely unclear. This study aimed to investigate how integrins facilitate the ACE2-mediated cellular entry of SARS-CoV-2. We first tested the susceptibility of a panel of human cell lines to SARS-CoV-2 infection using the spike protein pseudotyped virus assay and examined the expression levels of integrins in these cell lines by qPCR, western blot and flow cytometry. We found that integrin αvβ1 was highly enriched in the SARS-CoV-2 susceptible cell lines. Additional studies demonstrated that RGD (403-405)→AAA mutant was defective in binding to integrin αvβ1 compared to its wild type counterpart, and anti-αvβ1 integrin antibodies significantly inhibited the entry of SARS-CoV-2 into the cells. Further studies using mouse NIH3T3 cells expressing human ACE2, integrin αv, integrin β1, and/or integrin αvβ1 suggest that integrin αvβ1 was unable to function as an independent receptor but could significantly facilitate the cellular entry of SASR-CoV-2. Finally, we observed that the Omicron exhibited a significant increase in the ACE2-mediated viral entry. Our findings may enhance our understanding of the pathogenesis of SARS-CoV-2 infection and offer potential therapeutic target for COVID-19.

Keywords: ACE2; COVID-19; Integrin αvβ1; SARS-CoV-2; Viral entry.

MeSH terms

  • Angiotensin-Converting Enzyme 2 / metabolism
  • Animals
  • COVID-19* / metabolism
  • COVID-19* / virology
  • Humans
  • Mice
  • NIH 3T3 Cells
  • Receptors, Vitronectin / metabolism
  • SARS-CoV-2* / physiology
  • Spike Glycoprotein, Coronavirus / genetics
  • Spike Glycoprotein, Coronavirus / metabolism
  • Virus Internalization

Substances

  • Angiotensin-Converting Enzyme 2
  • integrin alphavbeta1
  • Receptors, Vitronectin
  • Spike Glycoprotein, Coronavirus
  • spike protein, SARS-CoV-2